Findings from serological surveys (in August 2020) to assess the exposure of adult population to SARS Cov-2 infection in three cities of Odisha, India

Author:

Kshatri Jaya Singh,Bhattacharya Debdutta,Kanungo Srikanta,Giri Sidhartha,Palo Subrata Kumar,Parai Debaprasad,Turuk Jyotirmayee,Mansingh Asit,Choudhary Hariram,Dash Girish Chandra,Mishra Niranjan,Satapathy D.M.,Sahoo Sanjaya Ku,Pati Sanghamitra

Abstract

AbstractBackgroundThere is always an uncertainty of epidemiological, serological infectivity and virulence of the emerging novel coronavirus. Antibody test can be used for assessing whether immunity has developed in the infected person after 5-7 days of illness and understand cumulative exposure levels to the infection, make inferences on the actual burden of infection, its geographical spread, effect on specific demographic/risk groups, gaps in testing and infection fatality rates.ObjectiveTo estimate and compare the sero-prevalence, hidden prevalence and determine the demographic risk factors associated with SARS-CoV-2 infection among adults in three largest cities of Odisha, India.MethodologyThis was a population based cross sectional serological survey carried out in August 2020 in the three largest cities of the state of Odisha. Sample size per city was estimated to be 1500 and participants were enrolled from the community using multi-stage random sampling from 25 clusters from each city. Data was collected using ODK based tools by household visits and 3-4 ml of blood samples were collected after informed consent. Samples were transported to testing lab where Serum was separated and tested for anti-SARS CoV-2 antibodies using automated CLIA platform. Statistical analysis was done using R-software packages.ResultsA total of 4146 participants from the 3 cities of Bhubaneswar (BBS), Berhampur (BAM) and Rourkela (RKL) participated. A total of 5635 households were approached and the average non response rate in the community was 17.4%. The gender weighted seroprevalence across the three cities was 20.78% (95% CI: 19.56%-22.05%). Seroprevalence was highest in BAM at 31.14% (95% CI: 28.69-33.66%) followed by 24.59% (95% CI: 22.39-26.88%) in RKL and 5.24% (95% CI: 4.10-6.58%) in BBS. While females reported a higher seroprevalence (22.8%) as compared to males (18.8%), there was no significant difference in seroprevalence across age groups. A majority of the seropositive participants were asymptomatic (93.87%). Among those who reported symptoms, the most common symptom was fever (68.89%) followed by cough (46.06%) and myalgia (32.67%). The case to infection ratio on the date of serosurvey was 1: 6.6 in BBS, 1:61 in BAM and 1:29.8 in RKL.ConclusionThe study found a high seroprevalence against COVID-19 in urban Odisha as well as high numbers of asymptomatic infections.

Publisher

Cold Spring Harbor Laboratory

Reference31 articles.

1. WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. [cited 2020 Sep 27]. Available from: https://covid19.who.int/?gclid=Cj0KCQjwzbv7BRDIARIsAM-A6-2k214RvC8sT16L4ebjaAg7FVCQF3VxjCXLzT9MZ57_vW_Sbg-igoMaAvbUEALw_wcB

2. Govt. of India, MoHFW, Dashboard [Internet]. [cited 2020 Sep 27]. Available from: https://www.mohfw.gov.in/

3. COVID-19: Odisha State Dashboard [Internet]. [cited 2020 Sep 27]. Available from: https://statedashboard.odisha.gov.in/

4. World Health Organization (WHO). Seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection [Internet]. 2020. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Seroepidemiology-2020.2

5. CDC. Overview of Testing for SARS-CoV-2 | CDC [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2020 Sep 19]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3